Slide 1: Scope Fluidics 1Q2025 update
SCOPE FLUIDICS 1Q2025 update 22 May 2025
Slide 2: Disclaimers
DISCLAIMERS Niniejsza prezentacja (“Prezentacja”) zawiera podstawowe informacje dotyczące Scope Fluidics S.A. („Spółka”) oraz grupy kapitałowej Scope Fluidics S.A. („Grupa”). Prezentacja została przygotowana wyłącznie w celu przedstawienia podstawowych informacji o Grupie i jej działalności. Prezent
Slide 3: Unique combination of competencies in technology, operations and financial areas
UNIQUE COMBINATION OF COMPETENCIES IN TECHNOLOGY, OPERATIONS AND FINANCIAL AREAS MANAGEMENT BOARD OF SCOPE FLUIDICS MARCIN IZYDORZAK PROF. PIOTR GARSTECKI SZYMON RUTA VICE PRESIDENT CEO VICE PRESIDENT, CFO Co-founder of Scope Fluidics Co-founder of Scope Fluidics Responsible for financial division,
Slide 4: Venture Studio - our values and vision for success
SCOPE FLUIDICS Venture Studio - our values and vision for success We address global challenges in healthcare and develop technologies with real, global impact. PEOPLE COURAGE We aim at +USD 109 markets and develop technologies that can readily be leveraged by large, multinational and global med-tech
Slide 5: Corporate structure supports execution of M&A transactions
VENTURE STUDIO BUSINESS MODEL Corporate structure supports execution of M&A transactions Each project in Scope Fluidics’ Group is developed in a Sold to Bio-Rad 100% ownership of the SPVs separate, legal entity (SPV) Laboratories August 2022 Each subsidiary is focused on the SUBSIDIARY SUBSIDIARY SU
Slide 6: PCR|ONE – from idea to commercialization
FIRST PROJECT COMMERCIALIZED PCR|ONE – from idea to commercialization Curiosity Diagnostics developing PCR|ONE, • 3 Letters of Intent from key industry players automated point-of-care PCR system with a high multiplexing potential and time-to-result under 20 min • ~12 months of intensive process and
Slide 7: Bacteromic
{22> BACTEROMIC
Slide 8: Bacteromic - User-centric design and compliance
BACTEROMIC - User Advantages User-centric design and compliance Analyzer Analyzer: • Capacity for 60 Cartridges – high throughput with Filling random access Disposable Device • <6-8h Time to Result Cartridge • LIS connectivity Filling Device: • Quick, fully automated procedure of inoculation & seali
Slide 9: Market analysis: Addressing critical global healthcare challenge
Market analysis Addressing critical global healthcare challenge Opportunity to serve a growing and evolving market demand Global AST diagnostics market (USD bn) 5,7 CAGR 4,0 5.5% Isolates • "AMR could cause 10 million deaths annually by 2050" (Jim O’Neill Report) • "Currently, AMR is linked to 1.27
Slide 10: Market analysis: Automated AST market
Market analysis Automated AST market Standard AST (16-24 h) Rapid AST (<8 h) MATURE MARKET EMERGING MARKET Isolates Vitek MicroScan WalkAway Sensititre Phoenix DEVELOPING MARKET Positive Blood Cultures No market Strictly private & confidential 10
Slide 11: AST market needs future-proof, informative, rapid and cost-effective system
AST market needs future-proof, informative, rapid and cost-effective system that offers synergies across isolate and PBC market segments Strictly private & confidential 11
Slide 12: Market analysis: AST market trends
Market analysis AST market trends • high throughput • high throughput Isolates • low price requirement • low price for rapid • slow is OK • rapid Positive Blood • low throughput • high throughput Cultures • high price requirement • low price for cost & throughput • must be rapid • rapid Strictly pri
Slide 13: Market analysis: First system to address both markets
Market analysis First system to address both markets • high throughput Isolates • low price requirement for rapid • slow is OK • high throughput • low price • rapid Positive Blood • low throughput Cultures • high price requirement for cost & throughput • must be rapid Strictly private & confidential
Slide 14: Ideal solution for evolving AST market
Ideal solution for evolving AST market • rapid AST • high-throughput • one panel for all bacteria • one box for PBC and isolates • broad antibiotic menu on a single card • true MIC • cost-effective manufacturing Potential for Bacteromic to rival the global AST space 14
Slide 15: Technology excellence – best AST offering on the market
Technology excellence – best AST offering on the market Overall scoring 63 57 39 37 35 35 34 32 30 System Bacteromic Future-proof real estate 5 4 3 4 3 3 1 3 3 (wells) PBC & Isolates relevance 5 5 1 1 1 1 1 1 1 PBC offering 5 5 3 4 3 3 3 4 3 attractiveness Isolates offering 5 5 3 1 1 1 1 1 1 attract
Slide 16: M&A process on track
BACTERIOMIC M&A process on track JP Morgan January Healthcare Conference San Francisco April ECCMID Wiena JP Morgan June Healthcare Symposium London ADLM July Chicago Jefferies November Healthcare Conference London 16
Slide 17: Discovery & new projects
Discovery & new projects
Slide 18: The process of creating new Special Purpose Vehicles
SCOPE DISCOVERY The process of creating new Special Purpose Vehicles Systemic selection and development of new projects BACTEROMIC - EDOCERA - - - HYBOLIC PCR | ONE Accelerating - the process - + - from - project selection - to - - STRATEGIC strategic - TRANSACTIONS STRATEGIC transaction - + + + + -
Slide 19: Edocera: AI-driven platform for early stroke detection
EDOCERA AI-driven platform with a life-saving device for early stroke detection PROBLEM SOLUTION Strokes often go undetected for hours, preventing timely treatment and contributing to over 12 million Our device leverages AI to analyze subtle signal stroke-related deaths annually, approx. 100 mln cha
Slide 20: Analysis of M&A transactions brings promising opportunities
Analysis of M&A transactions brings promising opportunities CLOSED M&A TRANSACTIONS TERMINATED wearable cardiac wearable cardiac health monitoring invasive heart attack monitors monitors platform warning system $925M $375M $400M $195M + USD 300m in + undisclosed milestone milestone payments payments
Slide 21: Hybolic: early detection of metabolic syndrome risk
HYBOLIC AI-driven platform with a life-saving device for early stroke detection PROBLEM SOLUTION The global prevalence of diabetes is steadily Early detection of metabolic syndrome risk through increasing, with projections indicating a significant monitoring key biomarkers for insulin resistance and
Slide 22: Analysis of M&A transactions brings promising opportunities
ANALYSIS OF M&A TRANSACTIONS BRINGS PROMISING OPPORTUNITIES CLOSED M&A TRANSACTIONS Early CGM development Early CGM development CGM CGM $3.7B $1.2B $1.6B undisclosed + undisclosed milestone payments Acquisition date 2001 2003 2022 2023 Buyer Medtronic Roche Owens&Minor Abbott Revenue USD 350 M USD 2
Slide 23: Where do we want to be?
SCOPE FLUIDICS Where do we want to be? By the end of 2025 having at least five new projects in the portfolio, 1 including at least two STRATEGIC TRANSACTIONS: in the form of special purpose vehicles 1. Sale of all shares in special purpose vehicles developing By the end of 2028 breakthrough technolo
Slide 24: How do we get there?
SCOPE FLUIDICS How do we get there? By the end of 2025 having at least five new projects in the portfolio, 1 including at least two Goal no 1 achieved in January 2025 in the form of special purpose vehicles • Maximizing the INVESTMEMNT By the end of 2028 value of BACTEROMIC 2 Closing at least two tr
Slide 25: 15 Years of Systematic Growth: Building an Even Stronger Future
15 Years of Systematic Growth: Building an Even Stronger Future From a 10k PLN start-up to a largest med-tech venture studio in CEE 2010 Founded for PLN 10k 2010-2015 Two generations of BlueBox, EUR 6m turnover 2012 Launch of Curiosity Diagnostics 2017 Founding of the Bacteromic company 2017 New Con
Slide 26: Financial track record – outstanding return on investment
SCOPE FLUIDICS Financial track record – outstanding return on investment and dynamic outlook for future developments. Bacteromic, Venture Studio with yearly USD 130m revenue from sales of PCR I One exits. USD 100m market cap (10x since IPO) USD 50m dividend payed out in 2023 BACTEROMIC developed to
Slide 27: Plans
NEXT STEPS Plans 27
Slide 28: Key value inflection points in MedTech development
BACTEROMIC Key value inflection points in MedTech development Commercial traction Team & facilities Positive market feedback First clients & revenue IP protection Profitability Market readiness Team of professionals & facility (labs, workshop) Compliance QMS & ISO Patent protection Compliance (QMS &
Slide 29: Benchmark transactions in diagnostics space
Benchmark transactions in diagnostics space Rapid AST for PBC Market traction $795m 2019 – Minority investment (MobiDIAG) 2021 – Distribution exclusivity $425m $550m 2022 – Acquisition for USD 425m (Specific Reveal) (MesaBiotech) Transaction value $275m $248m (Stilla Technologies) Rapid AST for UTI
Slide 30: Maximizing value in parallel with ongoing M&A process
NEXT STEPS - BACTEROMIC Maximizing value in parallel with ongoing M&A process 2025 2026 2027 ▪ A "fast detection" software for rapid bacterial ▪ A "fast detection" software for rapid bacterial ▪ Doubling of the production capacity by 2027 growth detection and antibiotic susceptibility growth detecti
Slide 31: Investment in the future
NEXT STEPS Investment in the future SCOPE DISCOVERY SCOPE FLUIDICS 2-3 additional SPVs launched - 4-5 SPVs in the Activities within the Scope necessary for the proper portfolio at the end of 2027 and efficient operation of the Group in 2025-2027 EDOCERA HYBOLIC 2025 - verification of selected techno
Slide 32: Multiple potential sources of financing
SCOPE FLUIDICS Multiple potential sources of financing STRATEGIC TRANSACTIONS VENTURE DEBT • Recommendation for keeping • Elevated costs profit from PCR|ONE milestone • Restrictions related to this form settlement of financing GRANTS TARGET CAPITAL • Long processes with limited • Stronger negotiatio
Slide 33: Thank you!
THANK YOU! INVESTOR RELATIONS relacjeinwestorskie@scopefluidics.com